
Release date: 2026-05-28 15:32:25 Article From: Lucius Laos Recommended: 35
The most common serious side effect of Tivozanib is hypertension. During treatment, your doctor will regularly monitor your blood pressure. If your blood pressure becomes too high, your doctor may prescribe antihypertensive medication or reduce the dose of Tivozanib. If blood pressure remains uncontrolled, your doctor may decide to interrupt or even discontinue treatment. If you are already taking antihypertensive medication, you need to watch for hypotension when your doctor reduces the dose of Tivozanib or stops treatment. Symptoms of hypertension include severe headache, blurred vision, difficulty breathing, irritability, confusion, or disorientation. If these occur, seek immediate medical attention.
p> Use of Tivozanib may increase the risk of blood clots. Clots can occur in the lungs (manifested as cough, chest pain, sudden difficulty breathing, or coughing up blood), in the legs or arms (pain, swelling), or in the eyes or brain (vision loss, mental status changes). If you have a history of stroke, mini-stroke, heart attack, diabetes, major surgery, or multiple traumas, you should be particularly vigilant. Tivozanib may also increase the risk of bleeding. If you experience abdominal pain or swelling, vomiting blood, coughing up blood, black stools, blood in urine, headache, or mental status changes, inform your doctor immediately, as temporary interruption of treatment may be necessary.
Tivozanib may cause heart failure, with symptoms including difficulty breathing during activity or lying down, weakness and fatigue, swelling of the ankles and feet, reduced exercise tolerance, and persistent cough with white or pink sputum. Your doctor will closely monitor these symptoms. For patients with cardiac arrhythmias, your doctor will use electrocardiogram or monitor blood calcium, magnesium, and potassium levels to assess the drug's impact. Patients with liver problems need regular liver function tests before and during treatment; your doctor may reduce the dosing frequency based on the situation. Thyroid function may also be affected, presenting as hypothyroidism, and requires regular monitoring.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:3842025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:5782024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:3622025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:3782025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:3592025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:4262025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:3492025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:3252025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643